CJC-1295 No DAC vs DAC: Pulsatile vs Sustained GH Release Research

CJC-1295 is a modified 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), available in two research formats that share the same receptor target but produce mechanistically distinct release patterns: with, and without, a Drug Affinity Complex (DAC).

The DAC Difference

The Drug Affinity Complex is a chemical modification that binds serum albumin, dramatically extending the peptide's circulating half-life.

• ·CJC-1295 (No DAC) — half-life of approximately 30 minutes, preserving a short, pulsatile GH release pattern that mimics the body's natural secretion rhythm
• ·CJC-1295 (DAC) — half-life of approximately 6–8 days via albumin binding, producing sustained, elevated GH and IGF-1 levels across the entire dosing interval rather than discrete pulses

Both act on the same GHRH receptor at the anterior pituitary; the DAC modification changes nothing about receptor engagement, only how long the peptide remains available to trigger it.

Research Implications of Each Pattern

| Variable | No DAC | DAC |

|---|---|---|

| GH release pattern | Pulsatile, mimics natural rhythm | Sustained, continuous elevation |

| Typical dosing frequency | Daily (often pre-sleep) | Once weekly |

| Research relevance | Physiological pulse-pattern studies, natural axis regulation | Steady-state GH/IGF-1 exposure studies |

| Pairing with Ipamorelin | Common — both act on complementary pathways for amplified pulses | Also studied, for sustained baseline + amplified daily pulses |

Researchers studying the natural regulatory feedback of the GH axis — including negative feedback from somatostatin — often prefer the No DAC pulsatile pattern, since sustained non-pulsatile elevation can blunt some of the physiological feedback dynamics under study. Researchers more interested in steady-state IGF-1 exposure and dosing convenience often select the DAC variant.

Stacking with Ipamorelin

Both variants are studied in combination with Ipamorelin, a ghrelin (GHSR) receptor agonist that acts through a separate pathway. Because CJC-1295 (either format) and Ipamorelin engage different receptors, their combined use is one of the more established synergy models in GH-axis research — see the full Ipamorelin/CJC-1295 synergy breakdown and the head-to-head comparison.

Reconstitution and Storage

Both variants are supplied as lyophilized powder and reconstituted with bacteriostatic water — approximately 3.0 mL for No DAC and 2.5 mL for DAC at the 5mg vial size. Store lyophilized powder at -20°C and reconstituted solution refrigerated at 2–8°C.

Shop CJC-1295 (No DAC) or CJC-1295 (DAC).

Note: CJC-1295 is sold by JA Performance strictly for laboratory and in vitro research use. Not for human consumption.